Indraneel Chakraborty
Biographic Data
| ID | 5736979 |
|---|---|
| NAME | Indraneel Chakraborty |
| GIVEN NAMES | Indraneel |
| FAMILY NAME | Chakraborty |
| SIGNATURE | CHAKRABORTY I |
| AFFILIATIONS | Institute of Bioinformatics and Applied Biotechnology |
| ORCID | 0000-0001-9389-7985 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 8 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2017 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 1 |
An analysis of deficiencies in the ethics committee data of certain interventional trials registered with the Clinical Trials Registry–India
There is widespread agreement that clinical trials should be registered in a public registry, preferably before the trial commences. It is also important that details of each trial in the public record are complete and accurate. In this study, we examined the trial sites and ethics committee (EC) data for 1359 recent Phase 2 or Phase 3 interventional trials registered with Clinical Trials Registry–India (CTRI), to identify categories of problems …
Rare disease patients in India are rarely involved in international orphan drug trials
We wished to determine whether rare diseases patients from India had been enrolled in international trials to develop novel orphan drugs. There are two reasons to be interested in this. (a) Different ethnic or racial groups may respond differently to a particular drug. India has huge ethnic diversity, and to exclude such participants is to severely limit the diversity of any trial; (b) Even if a suitable drug for a rare disease is available in In…
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
Clinical trial registries such as ClinicalTrials.gov (CTG) hold large amounts of data regarding trials. Drugs for rare diseases are known as orphan drugs (ODs), and it is particularly important that trials for ODs are registered, and the data in the trial record are accurate. However, there may be discrepancies between trial-related data that were the basis for the approval of a drug, as available from Food and Drug Administration (FDA) documents…
Income Inequality, Tax Policy, and Economic Growth
We investigate how the reduction of income inequality through tax policy affects economic growth. Taxation at different points of the income distribution has heterogeneous impacts on households’ incentives to work, invest, and consume. Using US state‐level data and micro‐level household tax returns over the last three decades, we find that reducing income inequality between low and median income households improves economic growth. However, reduc…
Income Inequality, Tax Policy, and Economic Growth
We investigate how the reduction of income inequality through tax policy affects economic growth. Taxation at different points of the income distribution has heterogeneous impacts on households’ incentives to work, invest, and consume. Using US state‐level data and micro‐level household tax returns over the last three decades, we find that reducing income inequality between low and median income households improves economic growth. However, reduc…
Income Inequality, Tax Policy, and Economic Growth
We investigate how the reduction of income inequality through tax policy affects economic growth. Taxation at different points of the income distribution has heterogeneous impacts on households’ incentives to work, invest, and consume. Using US state‐level data and micro‐level household tax returns over the last three decades, we find that reducing income inequality between low and median income households improves economic growth. However, reduc…
An analysis of deficiencies in the ethics committee data of certain interventional trials registered with the Clinical Trials Registry–India
There is widespread agreement that clinical trials should be registered in a public registry, preferably before the trial commences. It is also important that details of each trial in the public record are complete and accurate. In this study, we examined the trial sites and ethics committee (EC) data for 1359 recent Phase 2 or Phase 3 interventional trials registered with Clinical Trials Registry–India (CTRI), to identify categories of problems …
Rare disease patients in India are rarely involved in international orphan drug trials
We wished to determine whether rare diseases patients from India had been enrolled in international trials to develop novel orphan drugs. There are two reasons to be interested in this. (a) Different ethnic or racial groups may respond differently to a particular drug. India has huge ethnic diversity, and to exclude such participants is to severely limit the diversity of any trial; (b) Even if a suitable drug for a rare disease is available in In…
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
Clinical trial registries such as ClinicalTrials.gov (CTG) hold large amounts of data regarding trials. Drugs for rare diseases are known as orphan drugs (ODs), and it is particularly important that trials for ODs are registered, and the data in the trial record are accurate. However, there may be discrepancies between trial-related data that were the basis for the approval of a drug, as available from Food and Drug Administration (FDA) documents…
Clinical trial (3 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Medicine (3 works) · Bioinformatics (2 works) · Drug (2 works) · Internal Medicine (2 works) · Orphan drug (2 works) · Ambiguity (1 work) · Biology (1 work) · Biotechnology and Related Fields (1 work)